90 studies found for: Open Studies | "Hypercholesterolemia"
Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada
Study of Awareness and Detection of Familial Hypercholesterolemia
|3||Not yet recruiting||
Open Label Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Pediatric Subjects (10 to 17 Years of Age) With Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH).
French Observatory of Familial Hypercholesterolemia in Cardiology
Russian Familial Hypercholesterolemia Registry
Efficacy and Safety of FDC in High Risk Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Efficacy Study of Vitamin D and Statins to Treat Hypercholesterolemia
Postprandial Lipid Metabolism in Familial Hypercholesterolaemia:Effects of Fish Oils
Trial to Assess the Effects of P-OM3 on LDL-C in Subjects With Primary Hypercholesterolemia
MYOCARDIAL SILENT INFARCTIONS AND FIBROSIS IN FAMILIAL HYPERCHOLESTEROLEMIA (CHOLCOEUR)
The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository
Evaluation of Chylomicrons Metabolism in Sub-Clinical Atherosclerosis in Patients Whit Heterozigous Familial Hypercholesterolemia (FH) Treated With Statin Plus Ezetimibe
EFFECTS OF CARDICHOL, AN HERBAL DIETARY SUPPLEMENT, IN MODERATE HYPERCHOLESTEROLEMIA
A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Hypercholesterolemia.
A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Atherosclerosis in Familial Hypercholesterolemia
Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin
Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
† Indicates status has not been verified in more than two years